US 12,291,567 B2
Antibodies to granulocyte-macrophage colony stimulating factor and uses thereof
Cheng-Lun Ku, Taoyuan (TW); Yu-Fang Lo, Taoyuan (TW); Han-Po Shih, Taoyuan (TW); Jing-Ya Ding, Taoyuan (TW); Pei-Han Chung, Taipei (TW); and Yin-Ping Wang, Taipei (TW)
Assigned to Elixiron Immunotherapeutics (Hong Kong) Limited, Hong Kong (HK)
Filed by ELIXIRON IMMUNOTHERAPEUTICS (HONG KONG) LIMITED, Hong Kong (CN)
Filed on Mar. 10, 2021, as Appl. No. 17/198,229.
Application 17/198,229 is a continuation of application No. PCT/CN2019/110570, filed on Oct. 11, 2019.
Claims priority of provisional application 62/830,754, filed on Apr. 8, 2019.
Claims priority of provisional application 62/745,602, filed on Oct. 15, 2018.
Prior Publication US 2021/0309732 A1, Oct. 7, 2021
Int. Cl. C07K 16/24 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/243 (2013.01) [G01N 33/6863 (2013.01); C07K 2317/21 (2013.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/92 (2013.01); G01N 2333/535 (2013.01)] 18 Claims
 
1. An isolated antibody, which binds to granulocyte-macrophage colony-stimulating factor (GM-CSF), wherein the antibody comprises:
(a) a heavy chain variable domain (VH), which comprises a HC CDR1 of SEQ ID NO: 5, a HC CDR2 of SEQ ID NO: 6, and a HC CDR3 of SEQ ID NO: 7, and a light chain variable domain (VL), which comprises a LC CDR1 of SEQ ID NO: 8, a LC CDR2 of SEQ ID NO: 9, and a LC CDR3 of SEQ ID NO: 10;
(b) a variant of the antibody set forth in (a), wherein one of HC CDR1, HC CDR2, HC CDR3, LC CDR1, or LC CDR3 is selected from
(i) HC CDR1 of SEQ ID NO: 21 or 22,
(ii) HC CDR2 of SEQ ID NO: 23,
(iii) HC CDR3 of SEQ ID NO: 24, 25, 26 or 27;
(iv) LC CDR1 of SEQ ID NO: 28,
(v) LC CDR3 of SEQ ID NO: 29 or 30.